Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues finds that Johnson & Johnson's Natrecor (neseritide), the current market leader in the treatment of acute heart failure, will continue to dominate the market in 2009 despite recent negative publicity. However, Natrecor will face intense competition from Daiichi's Hanp (carperitide), and ESP Pharma/CardioPep's ularitide following the launch of these two drugs.

The new Pharmacor report entitled Acute Heart Failure also finds that disappointing results from two pivotal trials of Orion/Abbott's Simdax (levosimendan) have cast doubt over the future of this molecule. The report also forecasts that the drug market to treat acute heart failure will experience modest annual growth of 3.5% through 2009 and more robust growth of nearly 10% annually from 2009 to 2014.

"Levosimendan was poised for widespread launch but the results from the recent trials now makes this seem very unlikely," said Mark Thornton, Ph.D., analyst at Decision Resources, Inc. "The key to success in this market is to demonstrate a significant mortality benefit and an improvement in efficacy and safety profile as compared to currently available therapies, although this is proving extremely hard to achieve."

About Acute Heart Failure

Acute heart failure is the leading diagnosis at discharge from U.S. hospitals and is one of the most common causes of hospitalization for patients over 65 in the Western world. Hospital admissions for its treatment are set to increase worldwide owing to a number of factors including aging populations that are at a greater risk of cardiovascular disease.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:     Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Competition to Be Intense Among Health Insurers Offering Medicare Drug Plans in California, According to HealthLeaders-InterStudy

View Now